Adult Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis
Description
Adult Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis
Adult Vaccine Market is expected to reach US$ 26.7 Billion by 2027. Adult vaccination is one of the most cost-effective strategies available in public health today. Each year, vaccine-preventable diseases kill thousands of adults across the world. Adult immunization includes the administration of licensed vaccines provided to patients aged 18 years and older for medical indications. However, vaccines are used to prevent diseases and improve the body's immunity. A vaccine is a biological practice, contains an agent that resembles a disease-causing microorganism, and is made from weakened and killed forms of microorganisms.
Recently, the increasing prevalence of diseases and novel vaccine technologies has been significant drivers for the global adult vaccines market. In addition, increased research in vaccine technologies and increasing government support also support the growth of the global adult vaccines market. In 2021, by Pfizer Vaccine Product Pipeline, XTANDI™ (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also know n as metastatic castration-sensitive prostate cancer or mCSPC) (E.U.)
How COVID-19 has Benefited the Adult Vaccine Market
Pandemic COVID-19 had mixed impact on vaccines industry. Some of the vaccines vaccination rates have declined. On the contrary few vaccines vaccination rates have jumped such as flu vaccines. The launches of COVID-19 vaccines have made a huge impact on the overall growth of vaccines industry. The vaccines industry has registered a growth of Billion of USD in the year 2021. According to Renub Research report, Global Adult Vaccine Industry is projected to grow with a CAGR of 6% from 2021-2027.
Adult Vaccine Market Size was US$ 18.8 Billion in 2021
The global adult vaccines disease segment includes Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel and Miscellaneous, Varicella. Pneumonia is a disorder that drives lung contamination in one or both the lungs induced by viruses, bacteria organisms, or fungi; bacterial pneumonia is the most familiar in adults. However, adults are more prone to pneumococcal contaminations and even death. Pneumonia vaccines are primarily given to adults; in general, single-dose vaccines given to adults. These vaccines help provide immunizations against 13 types of pneumococcal bacteria that cause lung infection.
The viral infection due to flu in the respiratory system is called influenza. The influenza virus traverses through respiratory droplets, and it is contagious. It also spreads from one person to another while physical contact and talking, particularly in adults. Healthcare organizations all over the world, like the (CDC) Centers for Disease Control and Prevention, have suggested vaccines like baloxavir marboxil (Xofluza) for the treatment of influenza have recommended certain influenza vaccines such as baloxavir marboxil (Xofluza) to treat the symptoms in adults.
According to CDC 2019-2018, Vaccinated by disease:
• 45% of adults received the vaccine for Influenza
• 69% of adults receive a pneumococcal vaccination
• 49% of adolescents aged 13-17 received the HPV vaccination
Key Industry Players:
The key players operating in the vaccine industry include GlaxoSmithKline, plc.’s Vaccines Sales, Merck & Co. Vaccines Sales, Sanofi Pasteur’s Vaccines Sales, Pfizer, Inc.’s Vaccines Sales, Thoracic Aortic Aneurysm (TAA) CSL Limited sales. In 2021 – GlaxoSmithKline plc announced that they have introduce a (BLA) Biologics License Application to the U.S. FDA for their investigational vaccine PRIORIX and desires approval to use it against measles, mumps, and rubella (MMR) in the U.S. region. The vaccine was first registered in Germany and is presently licensed in over 100 countries globally.
Renub Research latest report “Adult Vaccines Market Disease wise ( Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel and Miscellaneous, Varicella) Numbers of Vaccinated Adults (Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, TdaP, Varicella) by company analysis (GlaxoSmithKline, plc.’s Vaccines Sales, Merck & Co. Vaccines Sales, Sanofi Pasteur’s Vaccines Sales, Pfizer, Inc.’s Vaccines Sales, Thoracic Aortic Aneurysm (TAA) CSL Limited sales)” provides a detailed analysis of Adult Vaccines Industry
Disease wise – Adult Vaccine Market has been covered from 11 viewpoints
1. Coronavirus (COVID-19)
2. Influenza
3. Cervical Cancer (HPV)
4. Zoster (Shingles)
5. MMR (Measles, Mumps, and Rubella Vaccine)
6. Pneumococcal
7. Meningococcal
8. Hepatitis
9. TdaP
10. Travel and Miscellaneous
11. Varicella
Disease wise – Numbers of Vaccinated Adults has been covered from 10 viewpoints
1. Coronavirus (COVID-19)
2. Influenza
3. Cervical Cancer (HPV)
4. Zoster (Shingles)
5. MMR
6. Pneumococcal
7. Meningococcal
8. Hepatitis
9. TdaP
10. Varicella
Company Insights
• Overviews
• Recent Developments
• Revenues
Company Analysis:
1. GlaxoSmithKline, plc.’s
2. Merck & Co.
3. Sanofi Pasteur’s
4. Pfizer, Inc.’s
5. CSL Limited
Adult Vaccine Market is expected to reach US$ 26.7 Billion by 2027. Adult vaccination is one of the most cost-effective strategies available in public health today. Each year, vaccine-preventable diseases kill thousands of adults across the world. Adult immunization includes the administration of licensed vaccines provided to patients aged 18 years and older for medical indications. However, vaccines are used to prevent diseases and improve the body's immunity. A vaccine is a biological practice, contains an agent that resembles a disease-causing microorganism, and is made from weakened and killed forms of microorganisms.
Recently, the increasing prevalence of diseases and novel vaccine technologies has been significant drivers for the global adult vaccines market. In addition, increased research in vaccine technologies and increasing government support also support the growth of the global adult vaccines market. In 2021, by Pfizer Vaccine Product Pipeline, XTANDI™ (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also know n as metastatic castration-sensitive prostate cancer or mCSPC) (E.U.)
How COVID-19 has Benefited the Adult Vaccine Market
Pandemic COVID-19 had mixed impact on vaccines industry. Some of the vaccines vaccination rates have declined. On the contrary few vaccines vaccination rates have jumped such as flu vaccines. The launches of COVID-19 vaccines have made a huge impact on the overall growth of vaccines industry. The vaccines industry has registered a growth of Billion of USD in the year 2021. According to Renub Research report, Global Adult Vaccine Industry is projected to grow with a CAGR of 6% from 2021-2027.
Adult Vaccine Market Size was US$ 18.8 Billion in 2021
The global adult vaccines disease segment includes Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel and Miscellaneous, Varicella. Pneumonia is a disorder that drives lung contamination in one or both the lungs induced by viruses, bacteria organisms, or fungi; bacterial pneumonia is the most familiar in adults. However, adults are more prone to pneumococcal contaminations and even death. Pneumonia vaccines are primarily given to adults; in general, single-dose vaccines given to adults. These vaccines help provide immunizations against 13 types of pneumococcal bacteria that cause lung infection.
The viral infection due to flu in the respiratory system is called influenza. The influenza virus traverses through respiratory droplets, and it is contagious. It also spreads from one person to another while physical contact and talking, particularly in adults. Healthcare organizations all over the world, like the (CDC) Centers for Disease Control and Prevention, have suggested vaccines like baloxavir marboxil (Xofluza) for the treatment of influenza have recommended certain influenza vaccines such as baloxavir marboxil (Xofluza) to treat the symptoms in adults.
According to CDC 2019-2018, Vaccinated by disease:
• 45% of adults received the vaccine for Influenza
• 69% of adults receive a pneumococcal vaccination
• 49% of adolescents aged 13-17 received the HPV vaccination
Key Industry Players:
The key players operating in the vaccine industry include GlaxoSmithKline, plc.’s Vaccines Sales, Merck & Co. Vaccines Sales, Sanofi Pasteur’s Vaccines Sales, Pfizer, Inc.’s Vaccines Sales, Thoracic Aortic Aneurysm (TAA) CSL Limited sales. In 2021 – GlaxoSmithKline plc announced that they have introduce a (BLA) Biologics License Application to the U.S. FDA for their investigational vaccine PRIORIX and desires approval to use it against measles, mumps, and rubella (MMR) in the U.S. region. The vaccine was first registered in Germany and is presently licensed in over 100 countries globally.
Renub Research latest report “Adult Vaccines Market Disease wise ( Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel and Miscellaneous, Varicella) Numbers of Vaccinated Adults (Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, TdaP, Varicella) by company analysis (GlaxoSmithKline, plc.’s Vaccines Sales, Merck & Co. Vaccines Sales, Sanofi Pasteur’s Vaccines Sales, Pfizer, Inc.’s Vaccines Sales, Thoracic Aortic Aneurysm (TAA) CSL Limited sales)” provides a detailed analysis of Adult Vaccines Industry
Disease wise – Adult Vaccine Market has been covered from 11 viewpoints
1. Coronavirus (COVID-19)
2. Influenza
3. Cervical Cancer (HPV)
4. Zoster (Shingles)
5. MMR (Measles, Mumps, and Rubella Vaccine)
6. Pneumococcal
7. Meningococcal
8. Hepatitis
9. TdaP
10. Travel and Miscellaneous
11. Varicella
Disease wise – Numbers of Vaccinated Adults has been covered from 10 viewpoints
1. Coronavirus (COVID-19)
2. Influenza
3. Cervical Cancer (HPV)
4. Zoster (Shingles)
5. MMR
6. Pneumococcal
7. Meningococcal
8. Hepatitis
9. TdaP
10. Varicella
Company Insights
• Overviews
• Recent Developments
• Revenues
Company Analysis:
1. GlaxoSmithKline, plc.’s
2. Merck & Co.
3. Sanofi Pasteur’s
4. Pfizer, Inc.’s
5. CSL Limited
Table of Contents
135 Pages
- 1. Introduction
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Driver
- 4.2 Challenges
- 5. Global Adult Vaccines Market
- 6. Market & Numbers Share – Adult Vaccines Analysis
- 6.1 Market Share
- 6.2 Population Share
- 7. Adult Vaccinated Numbers
- 8. Disease wise – Adult Vaccines Market
- 8.1 Coronavirus (COVID-19)
- 8.2 Influenza
- 8.3 Cervical Cancer (HPV)
- 8.4 Zoster (Shingles)
- 8.5 MMR (Measles, Mumps, and Rubella Vaccine)
- 8.6 Pneumococcal
- 8.7 Meningococcal
- 8.8 Hepatitis
- 8.9 TdaP
- 8.10 Travel and Miscellaneous
- 8.11 Varicella
- 9. Disease wise – Numbers of Adults Vaccinated
- 9.1 Coronavirus (COVID-19)
- 9.2 Influenza
- 9.3 Cervical Cancer (HPV)
- 9.4 Zoster (Shingles)
- 9.5 MMR
- 9.6 Pneumococcal
- 9.7 Meningococcal
- 9.8 Hepatitis
- 9.9 TdaP
- 9.10 Varicella
- 10. Mergers and Acquisitions in the Vaccine Industry
- 11. Vaccines and Regulator’s Interventions
- 11.1 Making and Meeting Standards of Quality and Safety
- 11.2 Vaccine Funding
- 12. Vaccines – Products and Pipeline
- 12.1 GSK Vaccine Product Pipeline
- 12.2 Merck Vaccine Product Pipeline
- 12.3 Sanofi Vaccine Product Pipeline
- 12.4 Pfizer Vaccine Product Pipeline
- 13. Porters Five Forces
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
- 14. Key Players
- 14.1 GlaxoSmithKline, plc.’s
- 14.1.1 Overview
- 14.1.2 Recent Development
- 14.1.3 Sales Analysis
- 14.2 Merck & Co.
- 14.2.1 Overview
- 14.2.2 Recent Development
- 14.2.3 Sales Analysis
- 14.3 Sanofi Pasteur’s
- 14.3.1 Overview
- 14.3.2 Recent Development
- 14.3.3 Sales Analysis
- 14.4 Pfizer, Inc.’s
- 14.4.1 Overview
- 14.4.2 Recent Development
- 14.4.3 Sales Analysis
- 14.5 CSL Limited
- 14.5.1 Overview
- 14.5.2 Recent Development
- 14.5.3 Sales Analysis
- List Of Figures:
- Figure-01: Global Adult Vaccines Market (Billion US$), 2016 – 2021
- Figure-02: Global – Forecast for Adult Vaccines Market (Billion US$), 2022 – 2027
- Figure-03: Global – Adult Vaccines Number (Million), 2016 – 2021
- Figure-04: Global – Forecast for Adult Vaccines Number (Million), 2022 – 2027
- Figure-05: Disease wise – Influenza Market (Million US$), 2016 – 2021
- Figure-06: Disease wise – Forecast for Influenza Market (Million US$), 2022 – 2027
- Figure-07: Disease wise – Cervical Cancer (HPV) Market (Million US$), 2016 – 2021
- Figure-08: Disease wise – Forecast for Cervical Cancer (HPV) Market (Million US$), 2022 – 2027
- Figure-09: Disease wise – Zoster (Shingles) Market (Million US$), 2016 – 2021
- Figure-10: Disease wise – Forecast for Zoster (Shingles) Market (Million US$), 2022 – 2027
- Figure-11: Disease wise – MMR (Measles, Mumps, and Rubella Vaccine) Market (Million US$), 2016 – 2021
- Figure-12: Disease wise – Forecast for MMR (Measles, Mumps, and Rubella Vaccine) Market (Million US$), 2022 – 2027
- Figure-13: Disease wise – Pneumococcal Market (Million US$), 2016 – 2021
- Figure-14: Disease wise – Forecast for Pneumococcal Market (Million US$), 2022 – 2027
- Figure-15: Disease wise – Meningococcal Market (Million US$), 2016 – 2021
- Figure-16: Disease wise – Forecast for Meningococcal Market (Million US$), 2022 – 2027
- Figure-17: Disease wise – Hepatitis Market (Million US$), 2016 – 2021
- Figure-18: Disease wise – Forecast for Hepatitis Market (Million US$), 2022 – 2027
- Figure-19: Disease wise – TdaP Market (Million US$), 2016 – 2021
- Figure-20: Disease wise – Forecast for TdaP Market (Million US$), 2022 – 2027
- Figure-21: Disease wise – Travel and Miscellaneous Market (Million US$), 2016 – 2021
- Figure-22: Disease wise – Forecast for Travel and Miscellaneous Market (Million US$), 2022 – 2027
- Figure-23: Disease wise – Varicella Market (Million US$), 2016 – 2021
- Figure-24: Disease wise – Forecast for Varicella Market (Million US$), 2022 – 2027
- Figure-25: Disease wise – Influenza Number (Million), 2016 – 2021
- Figure-26: Disease wise – Forecast for Influenza Number (Million), 2022 – 2027
- Figure-27: Disease wise – Cervical Cancer (HPV) Number (Million), 2016 – 2021
- Figure-28: Disease wise – Forecast for Cervical Cancer (HPV) Number (Million), 2022 – 2027
- Figure-29: Disease wise – Zoster (Shingles) Number (Million), 2016 – 2021
- Figure-30: Disease wise – Forecast for Zoster (Shingles) Number (Million), 2022 – 2027
- Figure-31: Disease wise – MMR Number (Million), 2016 – 2021
- Figure-32: Disease wise – Forecast for MMR Number (Million), 2022 – 2027
- Figure-33: Disease wise – Pneumococcal Number (Million), 2016 – 2021
- Figure-34: Disease wise – Forecast for Pneumococcal Number (Million), 2022 – 2027
- Figure-35: Disease wise – Meningococcal Number (Million), 2016 – 2021
- Figure-36: Disease wise – Forecast for Meningococcal Number (Million), 2022 – 2027
- Figure-37: Disease wise – Hepatitis Number (Million), 2016 – 2021
- Figure-38: Disease wise – Forecast for Hepatitis Number (Million), 2022 – 2027
- Figure-39: Disease wise – TdaP Number (Million), 2016 – 2021
- Figure-40: Disease wise – Forecast for TdaP Number (Million), 2022 – 2027
- Figure-41: Disease wise – Varicella Number (Million), 2016 – 2021
- Figure-42: Disease wise – Forecast for Varicella Number (Million), 2022 – 2027
- Figure-43: GlaxoSmithKline, plc.’s Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
- Figure-44: GlaxoSmithKline, plc.’s Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-45: Merck & Co. Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
- Figure-46: Merck & Co. Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-47: Sanofi Pasteur’s Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
- Figure-48: Sanofi Pasteur’s Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-49: Pfizer, Inc.’s Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
- Figure-50: Pfizer, Inc.’s Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-51: Thoracic Aortic Aneurysm (TAA)CSL Limited sales – Global Revenue (Million US$), 2016 – 2021
- Figure-52: Thoracic Aortic Aneurysm (TAA)CSL Limited sales – Forecast for Global Revenue (Million US$), 2022 – 2027
- List Of Tables:
- Table-01: Global – Adult Vaccines Market Share by Vaccine Type (Percent), 2016 – 2021
- Table-02: Global – Forecast for Adult Vaccines Market Share by Vaccine Type (Percent), 2022 – 2027
- Table-03: Global – Adult Vaccines Population Share by Vaccine Type (Percent), 2016 – 2021
- Table-04: Global – Forecast for Adult Vaccines Population Share by Vaccine Type (Percent), 2022 – 2027
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
